T-O (am): 0.470 (08:59:00)
Last updated: 17:00
Select columns required and click "Update" to save your preferences
Ann. Date | Qtr. Date | Q | FYE | Revenue [M] | PBT [M] | NP [M] | NPM | DPS | EPS | R. QoQ | R. YoY | E. QoQ | E. YoY | TTM EPS |
Adj. [M] |
NP [M] (adj) |
NPM (adj) |
EPS (adj) |
E. QoQ (adj) |
E. YoY (adj) |
TTM EPS (adj) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
28 Feb 23 | Q2 Dec 22 | 2 | 30 Jun 23 | 19.22 | 5.42 | 4.18 | 21.7% | 0.37 | 0.51 | 9.1% | 14.2% | 15.5% | 71.5% | ||||||||
25 Nov 22 | Q1 Sep 22 | 1 | 30 Jun 23 | 17.62 | 4.88 | 3.62 | 20.5% | 0.00 | 0.44 | 2.8% | 5.1% | ||||||||||
25 Aug 22 | Q4 Jun 22 | 4 | 30 Jun 22 | 17.14 | 3.37 | 3.81 | 22.2% | 0.37 | 0.49 | 8.5% | 115.3% | ||||||||||
26 May 22 | Q3 Mar 22 | 3 | 30 Jun 22 | 15.79 | 3.13 | 1.77 | 11.2% | 0.00 | 0.30 | 6.2% | 27.3% | ||||||||||
30 Mar 22 | Q2 Dec 21 | 2 | 30 Jun 22 | 16.83 | 3.34 | 2.44 | 14.5% | 0.00 | 0.41 |
EPS | 1.63 sen |
Trailing PE (Sector Median: 25.1) | 28.1 |
PEG | 0.32 |
Altman Z | 1.9 |
Beaver | 0.312 |
Current Ratio | 7.95 |
Debt-Equity (DE) Ratio | 0.27 |
FCF Yield | 1.85 % |
Revenue QoQ | 9.1 % |
Revenue YoY | 14.2% |
Profit QoQ | 15.51 % |
Profit YoY | 71.51 % |
Profit Margin (Sector Median: 9.8) | 19.17 % |
ROE (ROIC: 13.66) | 13.66 % |
Dividend Per Share (DPS) | 0.74 sen |
Dividend Yield (DY) | 1.61 % |
Ratios below have been recalculated after adjusting for One Off Gain/Loss detected from Quarterly reports
EPS | |
Trailing PE (Sector Median: 25.1) | |
Profit QoQ | |
Profit YoY | |
Profit Margin (Sector Median: 9.8) | |
ROE (ROIC: 13.67) | |
Altman Z |
Discounted Cash Flow (DCF) 5% Growth | |
Discounted Cash Flow (DCF) 10% Growth | |
Relative Valuation | |
Average Analysts FV based on 1 rating(s) |
Graham Formula | |
Graham Number | |
Net Tangible Asset (NTA) | 0.12 | Consistent QR FV |
Forward PE FV Calculator | |
Latest Profit (adjusted) [M] | 4.18 |
Expected Profit (Next QR) [M] | |
Expected Profit (After QR above) [M] | |
Expected Profit (After QR above) [M] | |
Estimated Fair Value |
Growth/Risk Fair Value Calculator | |
Expected growth (%) | |
Estimated downside / risk (%) | |
Estimated New DCF Fair Value |
Contract/Award Contribution Calculator | |
Contract/Award Value (in Million) | |
Estimated Contribution to Stock Price | |
Estimated New DCF Fair Value |
Profit-Based Calculator | |
Expected Profit (M) | |
for Year | |
Estimated New DCF Fair Value |
Revenue-Based Calculator | |
Expected Revenue (M) | |
for Year | |
Estimated New DCF Fair Value |
Market Pricing | |
Expected Profit (M) | 0 |
Expected Revenue (M) | 0 |
Expected Growth (%) | 0 |
DR CHONG SU-LIN reduced 100000.0 units announced on 09 Jan 2023 at ~RM0.49
Market Cap: 376 M.
Number of Shares: 818 M.
Adjusted Float: 0%.
Cengild Medical Berhad is an investment holding company and through its subsidiaries, the company is a healthcare provider specialising in the diagnosis and treatment of gastrointestinal and liver diseases and obesity. The company also provides consulting services and medical management services which comprise nursing services and clinical support services. Cengil Medical Berhad was incorporated in 2021 and is based in Kuala Lumpur, Malaysia.
Sectors: Healthcare, Health Care Providers, Penny Stocks
Code: 0243
Website: https://www.cengild.com/
Related Links: Bursa | Annual Report | Announcement
No warrants listed